Aktis Oncology, Inc.
AKTS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002035832
In the last 90 days, Aktis Oncology, Inc. insiders filed 0 open-market purchases and 5 sales; 113 institutions reported holding it in 13F filings for Q2 2026, worth $1.10B in total; Soros Fund Management is the only superinvestor holding it.
Holders of 5% or more of AKTS
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Aktis Oncology, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| MPM Bioventures 2018, L.P. | 13D | 19.30%10.3M shares | New | Jan 20, 20261 filing | Jan 20, 2026 | SEC |
| Eli Lilly & Co | 13D | 11.90%6.34M shares | New | Jan 15, 20261 filing | Jan 15, 2026 | SEC |
| VV Manager II, LLC | 13D | 10.90%5.83M shares | New | Jan 14, 20261 filing | Jan 14, 2026 | SEC |
| EcoR1 Capital, LLC | 13D | 9.10%4.86M shares | New | Jan 20, 20261 filing | Jan 20, 2026 | SEC |
| Blue Owl Capital Holdings LP | 13G | 5.92%3.16M shares | New | May 14, 20261 filing | May 14, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
5 Schedule 13D and 13G filings on Aktis Oncology, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| May 14, 20264:36 PM ET | Blue Owl Capital Holdings LP | 13G | 5.92%3.16M shares | New | Mar 31, 2026 | SEC |
| Jan 20, 20265:44 PM ET | MPM Bioventures 2018, L.P.and 12 others | 13D | 19.30%10.3M shares | New | Jan 12, 2026 | SEC |
| Jan 20, 20262:01 PM ET | EcoR1 Capital, LLCand 2 others | 13D | 9.10%4.86M shares | New | Jan 12, 2026 | SEC |
| Jan 15, 20266:02 AM ET | Eli Lilly & Co | 13D | 11.90%6.34M shares | New | Jan 12, 2026 | SEC |
| Jan 14, 20264:58 PM ET | VV Manager II, LLCand 3 others | 13D | 10.90%5.83M shares | New | Jan 12, 2026 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Aktis Oncology, Inc. shares.
No Form 144 notices for Aktis Oncology, Inc. are on file.